Orchard Therapeutics to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference
BOSTON and LONDON, Nov. 24, 2020 — Orchard Therapeutics (Nasdaq: ORTX) announced CEO Bobby Gaspar will participate in a pre-recorded fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference. This chat will be available for on-demand viewing in the Investors & Media section of their website and will remain accessible for approximately 90 days. Orchard is committed to developing innovative gene therapies for rare diseases, with a robust pipeline following its acquisition of GSK’s gene therapy portfolio in 2018.
- None.
- None.
BOSTON and LONDON, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that its chief executive officer, Bobby Gaspar, M.D., Ph.D. will participate in a pre-recorded fireside chat as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference. Management will also be available for one-on-one meetings on Tuesday, December 1, 2020.
The fireside chat is available for on-demand viewing under "Events" in the Investors & Media section of the company's website at www.orchard-tx.com and will remain available for approximately 90 days.
About Orchard
Orchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies. Our ex vivo autologous gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. In 2018, Orchard acquired GSK’s rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy. Orchard now has one of the deepest and most advanced gene therapy product candidate pipelines in the industry spanning multiple therapeutic areas where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist.
Orchard has its global headquarters in London and U.S. headquarters in Boston. For more information, please visit www.orchard-tx.com, and follow us on Twitter and LinkedIn.
Availability of Other Information About Orchard
Investors and others should note that Orchard communicates with its investors and the public using the company website (www.orchard-tx.com), the investor relations website (ir.orchard-tx.com), and on social media (Twitter and LinkedIn), including but not limited to investor presentations and investor fact sheets, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Orchard posts on these channels and websites could be deemed to be material information. As a result, Orchard encourages investors, the media, and others interested in Orchard to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Orchard’s investor relations website and may include additional social media channels. The contents of Orchard’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Contacts
Investors
Renee Leck
Director, Investor Relations
+1 862-242-0764
Renee.Leck@orchard-tx.com
FAQ
What date is the Piper Sandler 32nd Annual Virtual Healthcare Conference for Orchard Therapeutics?
How can I watch the fireside chat by Orchard Therapeutics CEO Bobby Gaspar?
What is the significance of the acquisition of GSK's gene therapy portfolio by Orchard?
How long will the fireside chat be available for viewing?
What does Orchard Therapeutics specialize in?
